TTA1 Cells

The TTA-1 cell line is derived from an undifferentiated thyroid carcinoma, also known as anaplastic thyroid carcinoma (ATC). This cell line exhibits the highly aggressive characteristics associated with ATC, including rapid proliferation and resistance to conventional therapies. Cytogenetic analysis of TTA-1 cells revealed extensive chromosomal abnormalities, with a modal chromosome number of 56?59 and numerous structural rearrangements. These features highlight the genetic instability typical of ATC. TTA-1 cells have been utilized extensively in research on tumorigenicity and oncogenesis. Studies have shown that tumorigenicity of TTA-1 cells can be modulated by genetic interventions, such as the introduction of chromosome 11 through microcell-mediated chromosome transfer. The addition of this chromosome led to partial suppression of tumorigenic properties, suggesting the presence of tumor suppressor genes on chromosome 11. Such studies provide insights into potential genetic therapeutic approaches to ATC. TTA-1 cells are known to secrete cytokines such as interleukin-6 (IL-6), which is implicated in cancer progression and the inflammatory responses associated with ATC. The production of cytokines by TTA-1 cells reflects their role in mediating tumor microenvironment interactions, making them a valuable model for studying both ATC biology and therapeutic resistance. Head-Neck cancer cell lines, Thyroid gland, Thyroid gland anaplastic carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1